狮子座的基础

2023年3月10日,

03/02 03/10/2023 | 02:01am EST信息:*必填字段利奥制药公司,全球领先的医学皮肤和图标plc(纳斯达克:ICLR)今天宣布了一项战略合作伙伴关系,将使利奥制药规模成规和成本有效的临床试验的执行,并将支持该公司的整体的野心建立一个最有效的和有效的临床项目组合执行机构。这个多媒体新闻发布功能。查看完整的版本:https://www.businesswire.com/news/home/20230309005472/en/伙伴关系的任务是改善皮肤病患者的生活进入创新新药临床试验和启动。下的伙伴关系将缩略词的速度,反映出要求迅速采取行动,应对今天的临床开发挑战。这也代表了利奥制药和图标的激情共同的价值观,敏捷,沟通和交付卓越。建筑在牛皮癣早期合作的成功试验,利奥制药愿进一步加强其转变的旅程,进入一个战略伙伴关系图标。合伙企业将利用完全外包和功能在定制外包模型和灵活的混合方法。利奥制药计划实现以下,同时保持一个以病人为中心的公司:传动效率在临床试验中重要和精益可伸缩性在各领域的专业知识在临床开发联合投资的区域内分散的临床试验获得大量的图标内部辅助服务的范围和规模经济访问外部数据、知识和技能以及技术合作公司股票类似的核心价值观“我们一直探索几个外包模型但发现混合采购模式是最有效的。与图标支持2030年的策略,因为它将帮助我们把创新治疗患者更快,同时支持一个更可持续的业务通过可扩展性和灵活性,”Jorg穆勒说,执行副总裁兼全球研发主管利奥制药。”图标的财富的服务和领先地位在临床开发将支持利奥制药的研发策略推动创新的基础上通过合作和支持保持竞争力。” In supporting LEO Pharma through this partnership, ICON will draw upon a team of over 500 professionals from across its business to deliver tailored solutions, bringing differentiating and enabling capabilities including its laboratories, Accellacare site-network, FIRECREST site management and decentralised clinical trial capabilities to create strategic advantage in how the trials are delivered. “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise. We take a flexible and integrated approach when working with our partners, utilising fully outsourced, hybrid and FSP models that complement our partner’s internal capabilities and enable them to achieve their strategic goals. It is also motivating for our employees to be working with a partner that shares our values and has a commitment to improving the lives of patients,” said Steve Cutler, CEO, ICON. Ends Follow @ICON_plc on Twitter: https://twitter.com/iconplc Connect with LEO Pharma on LinkedIn: www.linkedin.com/company/leo-pharma About ICON plc ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,100 employees in 111 locations in 53 countries as at December 31, 2022. For further information about ICON, visit: www.iconplc.com . About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion. ICON/ICLR-G